Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
MaxiCalc: A tool for online dosimetric evaluation of source-tracking based treatment verification in HDR brachytherapy

Hanlon MD, Smith RL, Franich RD

(2022), PHYS MEDICA, 94, 58-64

DOI: 10.1016/j.ejmp.2021.12.008

Real-world utilisation of brachytherapy boost and patient-reported functional outcomes in men who had external beam radiation therapy for prostate cancer in Australia

Ong WL, Evans M, Papa N, Millar J

(2022), CLIN TRANSL RAD ONCO, 37, 19-24

DOI: 10.1016/j.ctro.2022.08.009

Changing pattern of radiation therapy for bone metastases in an Australian population-based cohort of men with prostate cancer

Ong WL, Milne RL, Foroudi F, Millar JL

(2022), CLIN GENITOURIN CANC, 20(1), e7-15

DOI: 10.1016/j.clgc.2021.07.007

Establishing metastatic prostate cancer quality indicators using a modified Delphi approach

Zheng J, Sampurno F, George DJ, Morgans AK, Nguyen H, Abrahm JL, Bjartell A, Davis ID, Fitch MI, Gillessen S, Kanesvaran R, Matthew A, Millar JL, O'Sullivan JM, Payne H, Pouliot F, Yates P, Evans SM

(2022), CLIN GENITOURIN CANC, 20(2), e151-7

DOI: 10.1016/j.clgc.2021.11.018

Disparities in quality of life, social distress and employment outcomes in Australian cancer survivors

White VM, Lisy K, Ward A, Ristevski E, Clode M, Webber K, Emery J, Ijzerman MJ, Afshar N, Millar J, Gibbs P, Evans S, Jefford M

(2022), Support Care Cancer, 30(6), 5299-309

DOI: 10.1007/s00520-022-06914-w

Use of a PLA sleeve to remove electron enhancement in superficial X-ray therapy

Barbagallo C

(2022), Phys Eng Sci Med, 45(3), 1005-11

DOI: 10.1007/s13246-022-01163-x

Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registry

Bensley JG, Dhillon HM, Evans SM, Evans M, Bolton D, Davis ID, Dodds L, Frydenberg M, Kearns P, Lawrentschuk N, Murphy DG, Millar JL, Papa N

(2022), PSYCHO-ONCOLOGY, 31(3), 496-503

DOI: 10.1002/pon.5833

Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy

Ratnayake G, Reinwald S, Edwards J, Wong N, Yu D, Ward R, Smith R, Haydon A, Au PM, van Zelm MC, Senthi S

(2022), Radiother Oncol, 173, 299-305

DOI: 10.1016/j.radonc.2022.06.016

Application of an automated dose accumulation workflow in high-risk prostate cancer - validation and dose-volume analysis between planned and delivered dose

Ong A, Knight K, Panettieri V, Dimmock M, Tuan JKL, Tan HQ, Master Z, Wright C

(2022), Med Dosim, 47(1), 92-7

DOI: 10.1016/j.meddos.2021.09.004

Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

Azad AA, Tran B, Davis ID, Parente P, Evans M, Wong S, Brown S, Evans S, Millar J, Murphy DG, Papa N

(2022), Intern Med J, 52(8), 1339-46

DOI: 10.1111/imj.15288

HDR Brachytherapy and fractionation; does it matter?

Millar J

(2021), RADIOTHER ONCOL, 158, S40-41

Multi-Institutional Analysis of I-125 vs Pd-103 for LDR Prostate Brachytherapy Monotherapy

Tang C, Sander J, Thames H, Crook J, Blanchgard P, Ciezki J, Keyes M, Merrick G, Catton C, Sullivan F, Stock R, Mok H, Millar J, Moran B, Zelefsky M, Frank S

(2021), Brachytherapy, 20(3), S12-13

Lessons Learned from the Victorian Lung Cancer Registry: Opportunities for Quality Improvement in Lung Cancer Management and Outcomes

Stirling R, Brand M, Earnest A, Antippa P, Ball D, Bartlett J, Blum R, Briggs L, Caldecott M, Conron M, Jennings B, Langton D, Millar J, Mitchell P, Olesen I, Parente P, Richardson G, See K, Torres J, Underhill C, Wright G, Stenger M, McNeil J, Zalcberg J

(2021), J THORAC ONCOL, 16(3), S112

Demonstration of 3D source tracking HDR brachytherapy treatment verification in a phantom

Hanlon M, Smith R, Panettieri V, Millar J, Franich R

(2021), RADIOTHER ONCOL, 158, S54-S55

Are the Risk Groups Used for External Beam Treatment of Prostate Cancer Appropriate for Ldr Brachytherapy?

Crook J, Thames Hm Tang C, Blanchard P, Sanders J, Ciezki J, Keyes M, Morris WJ, Merrick G, Catton C, Raziee H, Stock R, Sullivan FJ, Anscher M, Millar J, Frank S

(2021), RADIOTHER ONCOL, 163, S35-S36

Setting up the Prostate Cancer Outcomes Registry of New Zealand: reflecting and influencing clinical practice

Mark S, Clarke J, Shand B., Millar J. Papa N

(2021), New Zealand Medical Journal, 134(1546), 79-88

Palliative radiotherapy for bone metastases at the end of life in Victoria

Ong WL, Foroudi F, Milne RL, Millar JL

(2021), MED J AUSTRALIA, 214(5), 236-7

DOI: 10.5694/mja2.50954

Trend in stereotactic radiation therapy use for management of bone and brain metastases in patients with renal cell carcinoma in Australia.

Ong WL, Siva S, Milne RL, Foroudi F, Millar JL

(2021), The Oncologist, 26(7), e1288-9

DOI: 10.1002/onco.13792

Geospatial and temporal variation of prostate cancer incidence

Wah W, S Ahern, S Evans, J Millar, Evans M, Earnest A

(2021), Public Health, 190, 7-15

DOI: 10.1016/j.puhe.2020.10.032

Oesophageal IGRT considerations for SBRT of LA-NSCLC: barium-enhanced CBCT and interfraction motion

Woodford K, Panettieri V, Ruben J, Davis S, Tran Le T, Miller S, Senthi S

(2021), Radiat Oncol, 16(1), 218

DOI: 10.1186/s13014-021-01946-8

1 2 3 4